{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.388","value":"-17.34"},{"groupId":"OG001","spread":"83.933","value":"32.78"},{"comment":"Only 1 participant is included in this arm, therefore Standard deviation cannot be calculated.","groupId":"OG002","spread":"NA","value":"-63.27"},{"groupId":"OG003","spread":"21.877","value":"0.74"},{"comment":"Only 1 participant is included in this arm, therefore Standard deviation cannot be calculated.","groupId":"OG004","spread":"NA","value":"0"},{"groupId":"OG005","spread":"27.658","value":"11.76"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with the indication of ovarian cancer, received Tisotumab vedotin 1.2 mg/kg (the recommended dose for phase II trials \\[RP2D\\] from the Dose Escalation part), administered as an intravenous infusion, over a minimum of 30 minutes 3 times every 4 weeks (3q4wk).","id":"OG000","title":"Part 2: Cohort Expansion: Cohort 1 3q4wk Ovarian"},{"description":"Participants with the indication of ovarian cancer, received Tisotumab vedotin 1.2 mg/kg (the recommended dose for phase II trials \\[RP2D\\] from the Dose Escalation part), administered as an intravenous infusion, over a minimum of 30 minutes 3 times every 4 weeks (3q4wk).","id":"OG001","title":"Part 2: Cohort Expansion: Cohort 2 3q4wk Cervical"},{"description":"Participants with the indication of ovarian cancer, received Tisotumab vedotin 1.2 mg/kg (RP2D from the Dose Escalation part), administered as an intravenous infusion, over a minimum of 30 minutes 3 times every 4 weeks (3q4wk). Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg, administered as an intravenous infusion once every 3 weeks (1q3w).","id":"OG002","title":"Part 2: Cohort Expansion: Cohort 3 3q4wk - 1q3w Ovarian"},{"description":"Participants with the indication of cervical cancer, received Tisotumab vedotin 1.2 mg/kg (RP2D from the Dose Escalation part), administered as an intravenous infusion, over a minimum of 30 minutes 3 times every 4 weeks (3q4wk). Due to severe ocular toxicity, participants switched to receive Tisotumab vedotin at 2.0 mg/kg, administered as an intravenous infusion once every 3 weeks (1q3w).","id":"OG003","title":"Part 2: Cohort Expansion: Cohort 4 3q4wk - 1q3w Cervical"},{"description":"Participants with the indication of ovarian cancer, received Tisotumab vedotin 2.0 mg/kg, administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3w); the revised dose and schedule due to severe ocular toxicity.","id":"OG004","title":"Part 2: Cohort Expansion: Cohort 5 1q3w Ovarian"},{"description":"Participants with the indication of cervical cancer, received Tisotumab vedotin 2.0 mg/kg, administered as an intravenous infusion, over a minimum of 30 minutes, once every 3 weeks (1q3w); the revised dose and schedule due to severe ocular toxicity.","id":"OG005","title":"Part 2: Cohort Expansion: Cohort 6 1q3w Cervical"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Baseline to end of trial (Part 2), up to 36 weeks","title":"Part 2: Anti-tumor Activity Measured by Percentage of Change in Sum of Lesion Measurements","type":"SECONDARY","unitOfMeasure":"percentage of change"}